Centre for Medical Imaging North-East Netherlands


The Center for Medical Imaging North East Netherlands (CMI NEN) NEN) is the result of a joint initiative of the University of Groningen (RuG)/University Medical Center Groningen (UMCG), University of Twente (UT), and Siemens Netherlands.

CMI NEN aims to secure a leading global position in innovative medical imaging with groundbreaking research & development, education and valorization. The initiative combines state-of-the-art research facilities, clinical practice and technology, and innovative education in one center. Clinical needs will drive the CMI-NEN’s research agenda.

Mission statement

The CMI-NEN research will focus on problem definition from three clinical fields: oncology (particularly breast, lung and prostate cancer), cardiovascular diseases and neuro(muscular) diseases. The research will concentrate on (combinations of) existing imaging technologies and new imaging technologies developed on those platforms: ultrasound, optics, magnetic resonance, X-rays and molecular imaging. Finally, four ‘enablers’ bring a third dimension to the strategic agenda to ensure accuracy, controllability, efficiency and effectiveness of research & development in medical imaging and its applications in diagnosis and treatment. The chosen enablers cover all imaging technology and disease areas. These are: targeted contrast agents, navigation technology, medical imaging informatics and MTA. The center will facilitate, stimulate and support knowledge transfer, education and entrepreneurship.

Partners & Network

CMI-NEN is founded by the University of Groningen (RuG), University Medical Center Groningen (UMCG), University of Twente (UT), and Siemens Netherlands. Each partner brings its own knowledge and experience into the mix, creating a powerful alliance.
The Center for Medical Imaging North East Netherlands (CMI-NEN) is the result of a joint initiative of the University of Groningen (RuG)/University Medical Center Groningen (UMCG), University of Twente (UT), and Siemens Netherlands.



Scope Early prostate cancer detection and treatment are of major importance to reduce mortality rate. Magnetic Resonance (MR) imaging provides images of the prostate where an early stage lesion can be visualized. The use of MR-compatible robotic systems for interventions in the prostate allows the i … Lees meer

Dream Imager

A prototype of the device will be ready for large scale testing and production in four years. Not only will it provide improved photoacoustic and ultrasound imaging, it will also be able to combine the images generated by both techniques. The expectation is that the new imager will improve and accel … Lees meer


Scope Lung cancer, COPD and CVD (so-called Big-3) are highly prevalent in the general population and are expected to cause most deaths by 2050 in China and the Western world. For this so-called Big-3, early treatment has been shown to delay or stop progression and allow therapy at a treatable stage … Lees meer


Scope This project will study subjects with an indication to undergo ICA, and aims to replace ICA. This pushes the indication of non-invasive imaging from the intermediate risk subjects (to reclassify to low/high risk) to the high-risk group. According to the guidelines, non-invasive imaging is not … Lees meer

Technical leader:


Medical leader:
Prof. Dr. M. Oudkerk

Prof. Matthijs Oudkerk (MD, PhD, FNASCI) is full professor in Radiology at the University of Groningen and is assigned at the University Medical Center Groningen. He is (co-) author of over 450 articles published in outstanding journals, and editor of several books. His main radiological interests are in quantitative imaging of cardiovascular diseases and lung cancer. Since January 2011, he is Medical Scientific Director of the CMI-NEN. In November 2016, he received a subsidy in the Programme Strategic Scientific Alliances (PSA) of the Royal Dutch Academy of Sciences (KNAW) in cooperation with the Chinese Ministry of Science and Technology (MOST) which is meant for research on early detection of cardiovascular disease, COPD and lung cancer in at least three large hospitals throughout China.